Almirall to participate in the 42nd Annual J.P. Morgan Healthcare Conference

BARCELONA, Spain. 19^th December, 2023 – Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced its participation in the upcoming 42^nd Annual J.P. Morgan Healthcare Conference in San Francisco, USA from 8^th-11^th January, 2024.

Carlos Gallardo, Chairman and CEO of Almirall, is scheduled to give a presentation at 9 am Pacific Standard Time (6pm CET) on 9^th January, 2024. The presentation will be available at https://www.almirall.com/investors and it will be streamed via webcast.

Furthermore, Almirall’s executive team will host one-on-one investor and business development meetings in San Francisco during the same period as the annual J.P. Morgan Healthcare Conference, running from 8^th to 11^th January, 2024. To explore this opportunity and schedule a meeting with Almirall's team, please do not hesitate to reach out to Mr. Pablo Divasson del Fraile via email at pablo.divasson@almirall.com.

About Almirall

Almirall is a global pharmaceutical company focused on medical dermatology. We collaborate with scientists and healthcare professionals to address patients' needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM). Throughout its 79-year history, Almirall has focused intensely on patients' needs. Almirall has a direct presence in 21 countries and strategic agreements in over 70, with about 1,800 employees. Total revenue in 2022 was €878.5 MM.

For more information, please visit almirall.com

Almirall’s legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the company considers reasonable. These statements involve risks and uncertainties beyond the control of the company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law